Profile data is unavailable for this security.
About the company
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
- Revenue in USD (TTM)0.00
- Net income in USD-1.35m
- Incorporated2010
- Employees--
- LocationMerrimack Pharmaceuticals IncOne Broadway, 14Th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 441-1000
- Fax+1 (617) 491-1386
- Websitehttps://www.merrimack.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eliem Therapeutics Inc | 0.00 | -14.53m | 216.44m | 9.00 | -- | 1.94 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 218.54m | -- | -- | -- | -- | -- | -- | -- | -- | -0.042 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 220.63m | 100.00 | -- | 7.95 | -- | 2.63 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 221.92m | 128.00 | -- | 1.05 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.35m | 223.75m | -- | -- | 0.992 | -- | -- | -0.0938 | 13.87 | 0.00 | 15.25 | 0.00 | -- | -- | -- | -1.02 | -23.52 | -1.12 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 224.23m | 46.00 | -- | 1.90 | -- | 13.82 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 224.95m | 51.00 | -- | 1.22 | -- | 13.93 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 225.18m | 10.00 | -- | 1.99 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 226.18m | 274.00 | -- | 1.09 | -- | 3.18 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Codexis Inc | 74.23m | -65.13m | 227.20m | 174.00 | -- | 2.87 | -- | 3.06 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 227.68m | 57.00 | -- | 0.8446 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 228.46m | 167.00 | -- | -- | -- | 1.22 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.40 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 82.75 | 69.13 | -22.98 | -82.25 | 1.31 | -5.00 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 230.60m | 249.00 | -- | -- | -- | 0.7639 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Data as of May 17 2024. Currency figures normalised to Merrimack Pharmaceuticals Inc's reporting currency: US Dollar USD
54.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Western Standard LLCas of 31 Mar 2024 | 2.17m | 14.95% |
| Newtyn Management LLCas of 31 Mar 2024 | 1.87m | 12.89% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 902.35k | 6.21% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 670.47k | 4.61% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 599.44k | 4.13% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 398.00k | 2.74% |
| Madison Avenue Partners LPas of 31 Mar 2024 | 387.22k | 2.67% |
| Sepio Capital LPas of 31 Mar 2024 | 298.55k | 2.05% |
| Invesco Capital Management LLCas of 31 Mar 2024 | 276.31k | 1.90% |
| Geode Capital Management LLCas of 31 Mar 2024 | 272.02k | 1.87% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
